Study on c-Met Targeted PET/CT Imaging in NSCLC
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-75
SponsorXilin Sun
About this trial
The investigators developed a 18F labeled small molecule, 18F-TSPF, based on c-Met TKI, as a targeted molecular imaging agent for noninvasive and repeatable detecting c-Met activation status.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Age range 18-75 years, open to both male and female participants;
Normal hepatic/renal function and cardiac function;
Expected survival of at least 12 weeks;
Good adherence to follow-up;
Disqualifiers
Severe abnormalities in liver and renal function and blood counts;
Patients planning to conceive;
Pregnant or lactating women;
Individuals unable to lie flat for thirty minutes;
Trial design
Design model
Single group
Treatments tested in this trial
18F-TSPF PET/CT
Diagnostic testEach subject receives interval imaging of 18F-TSPF PET/CT and 18F-FDG PET/CT, and further follow-up.
Treatment groups
88 Participants
are divided into 1 treatment groupGroup A: Experimental: 18F-TSPFExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Standardized Uptake Values
To quantify the PET, a volume of interest using a 3-D sphere, was placed over the primary lung tumor, lymph nodes and distant metastases avoiding necrosis, blood vessels and normal lung tissue as much as possible on a workstation (Advantage Workstation 4.6; GE Healthcare). The maximum standard uptake value (SUVmax) normalized to body weight (kBq/mL) was calculated within the region of interest. SUVmax of primary lesion and metastatic lesion in subjects with NSCLC are measured and used to analyze correlatation with pathology or gene detection.
Time frame
1 hourSponsors and contacts
Click on the lead sponsor to view all of their trials.
Xilin Sun
Lead sponsor
Harbin Medical University
Sponsor institution
Henan Provincial People's Hospital
Collaborator
Source ClinicalTrials.gov